Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq in midbrain of Coq9R239X mice treated with Rapamycin

ABSTRACT: RNA-Seq in midbrain of Coq9R239X mice treated with Rapamycin

PROVIDER: PRJEB31773 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3235740.fastq.gz	Fastqsanger.gz
	ERR3235750.fastq.gz	Fastqsanger.gz
	ERR3235741.fastq.gz	Fastqsanger.gz
	ERR3235751.fastq.gz	Fastqsanger.gz
	ERR3235732.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 25

Similar Datasets

RNA-Seq in midbrain of Coq9R239X mice treated with Rapamycin

Project description:Coq9R239X mice, a model of mitochondrial encephalopathy due to Coenzyme Q deficiency, were treated with Rapamycin administered in the chow at two different concentrations, i.e. 28 ppm and 225 ppm. The results are compared to those obtained in untreated Coq9R239X mice and untreated Coq9+/+ mice.

2019-03-21 | E-MTAB-7794 | biostudies-arrayexpress

Comparative gene expression analysis of splenic T cells derived from rapamycin and PBS-treated mice

Project description:The macrolide rapamycin is known for its immunosuppressive properties since it inhibits mTOR (mammalian target of rapamycin), which activity affects differentiation and functions of various innate and adaptive immune cells involved in graft-versus-host disease development. Since rapamycin procures immunosuppressive effects on the immune response, rapamycin is an attractive candidate for graft-versus-host disease prevention after allogeneic bone marrow transplantation We used an MHC class I and II mismatched parent into F1 bone marrow transplantation mouse model to elucidate the mechanisms of rapamycin on T cells in the context of graft-versus-host disease prevention. To define the impact of rapamycin therapy on T cells gene expression profile, we performed mircoarray analysis and compared gene expression profiles of sorted splenic T cells from rapamycin and PBS treated mice

2020-07-22 | GSE141415 | GEO

RNA sequencing of liver and kidney tissues from mice treated with rapamycin during development

Project description:RNA sequencing of liver and kidney tissues from mice treated with rapamycin during development

| PRJNA857456 | ENA

Methylation study of rapamycin treatment during development in mice

Project description:An Infinium microarray platform (HorvathMammalMethylChip320) was used to generate DNA methylation data from n=48 liver samples from mice. Treatment: encapsulated rapamycin treated or control mice

2022-08-05 | GSE210308 | GEO

Chronic Rapamycin treated bone marrow dendritic cells

Project description:Chronic Rapamycin treated bone marrow dendritic cells

| PRJNA664129 | ENA

Comparative gene expression analysis of cells derived from rapamycin and PBS-treated mice

Project description:Comparative gene expression analysis of cells derived from rapamycin and PBS-treated mice

| PRJNA593388 | ENA

Chronic Rapamycin treated bone marrow dendritic cells

Project description:Bone marrow dendritic cells were propaged with chronic treatment with Rapamycin and compared to vehicle treated cells.

2021-07-15 | GSE158161 | GEO

Comparative gene expression analysis of ex vivo isolated myeloid-derived suppressor cells (MDSCs) derived from rapamycin and PBS-treated mice

Project description:The macrolide rapamycin is known for its immunosuppressive properties since it inhibits mTOR (mammalian target of rapamycin), which activity affects differentiation and functions of various innate and adaptive immune cells involved in graft-versus-host disease development. Since rapamycin procures immunosuppressive effects on the immune response, rapamycin is an attractive candidate for graft-versus-host disease prevention after allogeneic bone marrow transplantation. Recently, an activating effect of rapamycin on the function of myeloid-derived suppressor cells (MDSCs), a subset of immune suppressive cells of myeloid origin was reported. However, the effect of rapamycin treatment on MDSCs induction and function in the management of graft-versus-host disease is largely unknown. We used an MHC class I and II mismatched parent into F1 bone marrow transplantation mouse model to elucidate the mechanisms of rapamycin on MDSCs in the context of graft-versus-host disease prevention. To define the impact of rapamycin therapy on MDSCs gene expression profile, we performed mircoarray analysis and compared gene expression profiles of ex vivo isolated MDSCs from rapamycin and PBS treated mice

2020-07-21 | GSE141414 | GEO

RNA sequencing of liver and kidney tissues from mice treated with rapamycin during development

Project description:RNA sequencing of mouse liver and kidney. UMHET pups were treated with diet containing encapsulated rapamycin or encapsulating material as a control from birth to 45 days of age, and tissues were collected at 2, 20-22 and 27-29 months of age from both males and females, and 3-5 samples per age, sex and treatment were sequenced.

2022-07-13 | GSE207865 | GEO

Global analyisis to study the bud27∆ and WT treated with rapamycin regarding to WT [RNA-seq]

Project description:RNA extraction for global analyisis and sequencing, to study the bud27∆ mutant and WT treated with rapamycin regarding to WT.

2020-06-22 | GSE131389 | GEO